News

FDA expands Lilly Jaypirca approval after 80% risk reduction in untreated CLL

+3

Health

FDA expands Lilly Jaypirca approval after 80% risk reduction in untreated CLL

Tom Gallagher · 2026-10-03T04:20:21.438Z

This approval opens up a strong new first-line option for CLL without the deletion, and that 80 percent risk drop could help a lot of patients stay stable longer.

8 sourcesUpdated Oct 3, 2026

+3

FDA expands Lilly Jaypirca approval after 80% risk reduction in untreated CLL — Photo: Deise Elen / Wikimedia Commons (Pexels)

Sponsored

The FDA on Oct. 2, 2026 expanded Eli Lilly’s Jaypirca (pirtobrutinib) as first-line treatment for adults with previously untreated CLL or SLL and no known 17p deletion. BRUIN CLL-313, a phase 3 trial of 282 adults, showed an 80% reduction in risk of progression or death versus bendamustine plus rituximab (HR 0.20). Median PFS was not reached with Jaypirca after 28 months’ median follow-up, versus 33.5 months with BR. Response rates were 94% versus 81% overall, 13% versus 21% complete, and 81% versus 60% partial. Dosing is 200 mg orally once daily. Lilly Oncology president Jacob Van Naarden said the milestone underscores versatility across the CLL continuum and has said primary use “remains in second line.” Dr. Jennifer A. Woyach said the approval rests on the trial’s delay in progression with consistent safety, that doctors can consider Jaypirca at initial therapy, and that many patients may get only one or two lines of therapy. CONTESTED: No source disputes the decision or figures. Rated coverage is center and right only.

Sponsored

In this story:Eli Lilly and Company

Where do you stand?

Eli Lilly and Company

Sponsored

How it spread

Broke Healio · Oct 1, 8:00 PM ETCenter +20hRight +20h8 sources +21h on

Claim check

What each side asserts, disputes — or leaves out entirely.

Analyzing the coverage…

Where do you land?

Whose framing of this story rings truest to you?

Sponsored

How each side headlines it

Left· 0 sources

No left coverage yet — a bubble gap.

Center· 1 source

“With FDA approval, Lilly’s BTK drug Jaypirca enters first-line CLL”

FiercePharma · Oct 2, 2026

Right· 1 source

“Eli Lilly's Jaypirca gains additional indication for untreated leukemia, lymphoma”

Seeking Alpha · Oct 2, 2026

Coverage

Sponsored

Comments (2)

Ask Genius by OpenServe:

Free account · your comment posts right after signup

Dana Whitfield⚡410h
I hope the expanded use leads to better access overall, though real-world results and side effect management will matter just as much as the trial numbers.
Tom Gallagher⚡610h
This approval opens up a strong new first-line option for CLL without the deletion, and that 80 percent risk drop could help a lot of patients stay stable longer.

Sponsored

More on this story

Back to News

Health

FDA recalls 747,844 potentially nonsterile eye products

The FDA classified a recall of 747,844 eye-drop and eye-ointment products made by Sterling Pharmaceutical Services as Class II because their sterility cannot be assured. Consumers should check product names, lot numbers and expiration dates against the FDA’s recall list and stop using any affected products.

6 sources

Business

FDA extends review of Novo Nordisk hemophilia drug over manufacturing issues

The FDA has extended its review of Novo Nordisk’s denecimig, a potential hemophilia A treatment, because the company is addressing manufacturing-facility issues. The agency has not raised concerns about the drug’s clinical safety or efficacy and has set no new decision date; Novo is targeting a U.S. launch in the first half of 2027.

6 sources

Sponsored

Health

FDA Finds Cyclospora at Mexican Outbreak-Linked Sites

FDA found Cyclospora in a wastewater tank and drainage ditch at Taylor Farms Mexico sites linked to an outbreak that sickened nearly 13,000, and closed its probe.

6 sources